Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: December 14, 2022
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 48.89 million |
|
Revenue Forecast in 2031 |
US$ 66.79 million |
|
CAGR |
3.5% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, global epilepsy with myoclonic-atonic seizures therapeutics market was valued at US$ 48.89 million in 2022 and is expected to register a revenue CAGR of 3.5% to reach US$ 66.79 million by 2031.
Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market Fundamentals
Myoclonic-atonic epilepsy (MAE) is an uncommon form of pediatric epilepsy characterized by myoclonic-atonic seizures, frequently identified by jerking muscular spasms followed by abrupt muscle limpness. Between the ages of 7 months and 6 years (peaking between 2 and 4 years), myoclonic-atonic epilepsy develops. Around 85% of the afflicted children had normal development before the beginning of seizures; the remaining 15% have mild psychomotor abnormalities, mostly impacting speech. The most improbable onset times are before 6 months or beyond 6 years. Generalized tonic-clonic seizures that are feverish, and afebrile seizures first manifest in two-thirds of patients before myoclonic-atonic seizures do. They often last for a long period, happen frequently, and most do so during the day. Myoclonic absences, atonic seizures, and myoclonic-atonic seizures emerge after a few weeks or months of intermittent generalized tonic-clonic seizures. These happen many times per day. These regular seizure episodes persist for one to four years. One-third of patients experience myoclonic-atonic status epilepticus, which can linger for hours or even days. This shows up as repeated myoclonic and atonic fits intermingled with varied degrees of cognitive impairment or cloudiness of awareness, which is often severe. Continuous facial myoclonus of the lips and eyelids is possible, along with the rapid movement of the limbs and atonic seizures marked by head swaying or falls. Drooling, shakiness, and speech impediment may also be present. Over the course of one or two years, myoclonic-atonic status epilepticus may happen many times. Each episode includes elements of abnormal absences, myoclonus, and atonia to varying degrees, with long-lasting effects on cognitive function. The kid seems stupefied, hypokinetic, and indifferent. It is possible to see barely perceptible myoclonic contractions as well as erratically twitching hands and facial muscles.
Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market Dynamics
The economic burden of the disease is rising, according to estimates, epilepsy affects 49 out of every 100,000 persons in high-income nations. Around 3.4 million Americans have epilepsy, according to the CDC (Centers for Disease Control and Prevention), and 470,000 are under 17. This number can reach 139 per 100,000 in low- and middle-income nations.
It has been observed that low- and middle-income nations have a sizable patient population of epilepsy sufferers. The patient pool is actually rather tiny in high-income nations. Due to exorbitant treatment costs and a lack of awareness, almost three-quarters of persons with epilepsy in low-income countries cannot obtain treatment. As a result, several organizations are making significant efforts to close the diagnostic and treatment gap and make the therapy accessible. For instance, the Epilepsy Foundation (U.S.), in partnership with community and network partners, connects the people, information, and resources necessary to address the complex health issues related to seizures and epilepsy and supports education, policy, research, and systemic change that fosters measurably and permanently better outcomes for all people living with epilepsy.
However, limitations regarding the diagnosis and treatment gaps are the main limiting factors. A treatment gap (TG) is the proportion of persons with active epilepsy who are not receiving adequate or appropriate treatment (diagnostic and therapeutic), represented as a percentage of all people with active epilepsy. Patients with epilepsy frequently do not obtain the proper care in underdeveloped nations. According to reports, a number of variables, such as poverty, stigma, cultural views, inadequate infrastructure for health care delivery, lack of access to or awareness about AEDs, and a lack of qualified personnel, impact this gap.
Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market Ecosystem
Global epilepsy with myoclonic-atonic seizures therapeutics market has been analyzed from the following perspectives by drug, distribution channel, and region.
Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market by Drug
Based on the drug, the global epilepsy with myoclonic-atonic seizures therapeutics market has been segmented into levetiracetam, sodium valproate, topiramate, others (lamotrigine, clobazam, zonisamide, ethosuximide, and rufinamide).
The levetiracetam drug segment will likely dominate the global market with a 4.0% revenue CAGR. It is also expected to register the highest CAGR during the forecast period. Levetiracetam is a broad-spectrum AED that binds to the synaptic vesicle protein SV2A and has similar chemical structures to other pyrrolidone derivatives like piracetam and brivaracetam. It is indicated for use in adults as a monotherapy for treating partial-onset seizures and an adjunctive medication for myoclonic and generalized tonic-clonic seizures.
Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market by Distribution Channel
Based on the distribution channel, the global epilepsy with myoclonic-atonic seizures therapeutics market has been segmented into hospital, retail, and online pharmacies.
The hospital pharmacy segment will likely dominate the market in 2022 with a share of 53%. Patients who have epilepsy with myoclonic-atonic seizures depend on their drugs to keep their daily lives feeling normal. Hospital pharmacists and doctors are a crucial part of the segment as pharmacists help patients with the disease and provide the best care possible because it is a challenging condition requiring professionals' time and attention. Furthermore, the number of hospitals is increasing, and these facilities provide suitable reimbursement policies, contributing as key drivers of hospital pharmacy expansion.
Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market by Region
Based on the region, the global epilepsy with myoclonic-atonic seizures therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominates global epilepsy with the myoclonic-atonic seizures therapeutics market with a 36.50% share. The United States is expected to be the largest market due to better healthcare infrastructure and rising cases of epilepsy. The top-notch healthcare infrastructure encourages higher treatment and diagnostic rates, boosting the market growth. The region holds a significant share of the global market due to the patient population's increased healthcare expenditures toward novel treatment alternatives and the presence of major businesses with their pipeline candidates and planned launches. For instance, in January 2020, the FDA approved VALTOCO nasal spray by Neurelis, Inc., for use with epilepsy drugs in children 6 years old or older.
Europe is expected to show substantial growth during the forecast period. The UK is the leading market in revenue contribution to the European market. It is expected to hold its leading position until the end of the forecast period because this market is less conservative than others. The UK typically evaluates the effectiveness of any new antiepileptics drug before being introduced to the rest of Europe. Due to its larger population and a high number of epilepsy patients, Germany is the second largest market in Europe, while the French market completes the top three in terms of revenues. Furthermore, the increasing demand for advanced healthcare services in the region is mainly responsible for market expansion. On the other hand, the market players are also acquiring other firms to expand their product portfolio. For instance, in January 2022, UCB announced that they had acquired Zogenix for US$ 1.9 billion, adding Fintepla (fenfluramine), a licensed drug for treating seizures related to Dravet syndrome, a rare form of pediatric epilepsy.
Asia Pacific is the fastest-growing region, with a revenue CAGR of 4.0%. Asia Pacific has a large share of the patient population suffering from epilepsy, and there is a vast treatment gap in the region mainly driven by flaws in healthcare delivery and social discrimination resulting from cultural beliefs about the disease. A study reported that approximately 5.3 epileptic seizures occur for every 1,000 children in Japan. Likewise, in China, reported estimates of the prevalence of active childhood epilepsy vary from 0.48% to 8.51%, while the estimated incidence rate is between 0.22% to 0.29%. The China Association against Epilepsy is vital in stimulating epilepsy interest. Nearly 20 anti-seizure medications are available in China.
Epilepsy with Myoclonic-Atonic Seizures Therapeutics Competitive Landscape
The prominent players in the global epilepsy with myoclonic-atonic seizures therapeutics market are:
Epilepsy with Myoclonic-Atonic Seizures Therapeutics Strategic Developments
Myoclonic-atonic epilepsy (MAE) is an uncommon form of pediatric epilepsy characterized by myoclonic-atonic seizures, frequently identified by jerking muscular spasms followed by abrupt muscle limpness. Between the ages of 7 months and 6 years (peaking between 2 and 4 years), myoclonic-atonic epilepsy develops.
North America region dominated the global market in 2022.
The estimated market size of the epilepsy with myoclonic-atonic seizures therapeutics market in 2031 will be US$ 66.79 million.
The revenue CAGR of epilepsy with myoclonic-atonic seizures therapeutics market during the forecast period will be 3.5%.
The levetiracetam drug segment led global epilepsy with the myoclonic-atonic seizures therapeutics market.
*Insights on financial performance are subject to the availability of information in the public domain